Osteoboost provides a prescription‑only, FDA‑cleared wearable belt that delivers calibrated low‑amplitude, high‑frequency vibration to the lumbar spine and hips, offering a drug‑free, at‑home therapy for postmenopausal women with osteopenia. Clinical trials show the device reduces vertebral and hip bone‑density loss by up to 85 % while the companion iOS app tracks sessions and compliance.
Funding
Funding not disclosed
Founders
Product
Problem
Postmenopausal women with osteopenia experience accelerated bone loss that increases fracture risk, yet existing therapies are limited to drugs with potential side effects or require frequent clinic visits and specialized equipment. Early‑stage, non‑pharmacologic options that can be integrated into daily life are scarce, leaving many patients without an effective, convenient intervention.
Solution
Osteoboost delivers a prescription‑only, FDA‑cleared wearable belt that provides precision vibration therapy to the lumbar spine and hips. The device emits low‑amplitude, high‑frequency mechanical stimulation (20‑40 Hz, 0.1–0.3 g) calibrated in real time to mimic the bone‑building effects of high‑impact exercise. A 30‑minute daily session can be performed while standing or walking, allowing patients to incorporate treatment into routine activities without additional appointments. Clinical data from a 12‑month, randomized, double‑blind, sham‑controlled trial show an 85 % reduction in vertebral bone‑density loss, an 83 % reduction in vertebral strength loss, and a 55 % reduction in hip‑density loss compared with placebo, with no device‑related serious adverse events. The system includes a companion iOS app for session tracking and guidance, and is available in three sizes to ensure a personalized fit.
Target Audience
Postmenopausal women in the United States diagnosed with osteopenia (DXA T‑score –1.0 to –2.49) seeking a non‑drug, at‑home therapy; and healthcare providers (primary care, OB‑GYN, endocrinology, rheumatology) who prescribe bone‑health interventions.
Features
- Wearable nylon belt with integrated motor delivering calibrated low‑amplitude vibration directly to the sacrum, lumbar spine, and hips.
- Embedded pressure sensor and automatic calibration routine ensures therapeutic dose (0.1–0.3 g) before each session.
- FDA De Novo Class II clearance as the first drug‑free prescription treatment for osteopenia.
- Proven efficacy: 85 % reduction in vertebral bone‑density loss, 83 % reduction in vertebral strength loss, 55 % reduction in hip‑density loss in a 12‑month pivotal trial.
- 30‑minute daily treatment while standing or walking; no need for dedicated exercise equipment or clinic visits.
- Companion iOS app (Android pending) provides setup assistance, session logging, step and calcium intake tracking, and compliance reminders.
- Three belt sizes (32‑40 in, 40‑48 in, 48‑56 in) with magnetic clasp for quick donning; battery lasts for multiple sessions and indicates charge level via LED indicators.
- 1‑year limited warranty, free shipping, 30‑day money‑back guarantee, and optional telehealth prescription service.